The use of intravenous immunoglobulin in Miller Fisher syndrome.

Abstract

We report a patient with Miller Fisher syndrome who was treated with an intravenous high-dose of immunoglobulin. This syndrome is considered to be a benign variety of acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome). However, there have been several reports of the need for ventilatory support and a few cases have had a fatal outcome. We observed a case of progressive Miller Fisher syndrome in a 3-year-old boy. Following 2 episodes of apnea lasting about 50 s each, he was treated with intravenous immunoglobulin (400 mg/kg/day) for 5 consecutive days. His respiratory state, general muscle strength, truncal ataxia and emotional state improved remarkably after this therapy.

• Authors: Y Arakawa, M Yoshimura, S Kobayashi, K Ichihashi, M Miyao, M Y Momoi, M Yanagisawa
• Journal: Brain & development (Brain Dev) 1993 May-Jun Vol. 15 Issue 3 Pg. 231-3 ISSN: 0387-7604 [Print] Netherlands
• PMID: 8214351 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoglobulins, Intravenous

Topics

• Ataxia (therapy)
• Child, Preschool
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Male
• Ophthalmoplegia (therapy)
• Polyradiculoneuropathy (therapy)
• Reflex
• Syndrome